Vol. 3 No. 1: 2006...2009: Now we know T-cell lymphomas better, Bologna, Italy, 16-18 March 2009

Published: 2009-06-11

Articles

T-cell and natural killer-cell lymphomas An update based on the 2008 WHO classification

E.S. Jaffe

https://doi.org/10.4081/hmr.v3i1.521

199

PDF: 235
- PDF
First line therapy for peripheral T-cell lymphoma

D. Sibon

https://doi.org/10.4081/hmr.v3i1.522

152

PDF: 1222
- PDF
Treatment of natural killer/T-cell lymphoma

R Liang

https://doi.org/10.4081/hmr.v3i1.523

202

PDF: 1187
- PDF
The role of positron emission tomography in T-cell lymphoma and T-cell specific response criteria

BD Cheson

https://doi.org/10.4081/hmr.v3i1.524

201

PDF: 442
- PDF
Epigenetic approaches. Histone deacetylase inhibitors: vorinostat. A new treatment option for advanced cutaneous T-cell lymphoma

M Duvic

https://doi.org/10.4081/hmr.v3i1.525

230

PDF: 308
- PDF
Panobinostat (LBH589): a novel pan-deacetylase inhibitor with activity in T cell lymphoma

HM Prince, M Prince

https://doi.org/10.4081/hmr.v3i1.526

317

PDF: 4312
- PDF
Activity of Belinostat in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma

F Foss, R Advani, K Hymes, B Pohlman, E Jacobsen, J McDonnell, A Lerner

https://doi.org/10.4081/hmr.v3i1.527

223

PDF: 324
- PDF
Gene expression profiling of peripheral T-cell lymphoma: from bench to bedside

PP Piccaluga, M Rossi, A Gazzola, MR Sapienza, C Mannu, S Righi, C Agostinelli, MT Sista, SA Pileri

https://doi.org/10.4081/hmr.v3i1.528

200

PDF: 270
- PDF
Angioimmunoblastic T-cell lymphoma: a tumor of follicular helper T cells derivation with clinical and pathological relevance

P Gaulard, Y-L Huang, C Thielen, L de Leval

https://doi.org/10.4081/hmr.v3i1.529

177

PDF: 854
- PDF
Anaplastic large cell lymphoma, ALK-positive and anaplastic large cell lymphoma ALK-negative

G Delsol, L Brugières, P Gaulard, E Espinos, L Lamant

https://doi.org/10.4081/hmr.v3i1.530

371

PDF: 776
- PDF
Plitidepsin is active in peripheral T-cell lymphoma: a subset analysis from an ongoing multicenter phase II trial

C Ferme, MV Mateos, S Szyldergemajn, E Zucca, S Extremera, J Briones, G Alessandro, V Ribrag

https://doi.org/10.4081/hmr.v3i1.531

171

PDF: 180
- PDF
Monoclonal antibody therapy of T cell lymphoma: single agent trials of anti-CD2 (Siplizumab) and anti-CD4 (Humax-CD4)

JE Janik, D O’Mahony, TA Waldmann, JC Morris

https://doi.org/10.4081/hmr.v3i1.532

315

PDF: 337
- PDF
Development of LY2334737, an oral gemcitabine prodrug for continuous administration. Perspectives for the therapy of mature T-cell and NK-cell lymphomas

O Shonukan, AH Dantzig, S Kloeker-Rhoades, I Garcia-Ribas

https://doi.org/10.4081/hmr.v3i1.533

267

PDF: 391
- PDF
Forodesine

V Gandhi

https://doi.org/10.4081/hmr.v3i1.534

149

PDF: 297
- PDF
Pentostatin in peripheral T-cell lymphomas

C Dearden

https://doi.org/10.4081/hmr.v3i1.535

174

PDF: 493
- PDF
Preclinical evaluation of sorafenib against B- and T-cell lymphoma

N Schuelper, B Chapuy, T Relander, L Truemper, G Wulf

https://doi.org/10.4081/hmr.v3i1.536

164

PDF: 123
- PDF
Immune modulation as a treatment strategy in angioimmunoblastic T-cell lymphoma

R Advani

https://doi.org/10.4081/hmr.v3i1.537

176

PDF: 106
- PDF
M. Santucci Cutaneous T-cell lymphomas: histology

M Santucci

https://doi.org/10.4081/hmr.v3i1.538

129

PDF: 1425
- PDF
Cutaneous T-cell lymphoma, new insights

MB Wozniak, SM Rodriguez Pinilla, R Villuendas, M Herrera, PL Ortiz, MA Piris

https://doi.org/10.4081/hmr.v3i1.539

172

PDF: 155
- PDF
Zanolimumab (Humax-CD4), a fully human monoclonal antibody with significant clinical responses in cutaneous T-cell lymphoma

YH Kim

https://doi.org/10.4081/hmr.v3i1.540

228

PDF: 435
- PDF
Forodesine

EA Olsen

https://doi.org/10.4081/hmr.v3i1.541

138

PDF: 112
- PDF
Gemcitabine

M Tani, L Alinari, A Broccoli, E Derenzini, M Fina, L Gandolfi, E Marchi, C Pellegrini, V Stefoni, F Venturini, PL Zinzani

https://doi.org/10.4081/hmr.v3i1.542

144

PDF: 163
- PDF
Pegylated, liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphoma: an update

S Pulini, S Rupoli, G Goteri, R Alterini, M Cantonetti, A Fabbri, P Quaglino, N Pimpinelli

https://doi.org/10.4081/hmr.v3i1.543

226

PDF: 353
- PDF
Innovative treatments: bexarotene

M Duvic

https://doi.org/10.4081/hmr.v3i1.544

167

PDF: 306
- PDF
Innovative treatments: bortezomib

PL Zinzani

https://doi.org/10.4081/hmr.v3i1.545

148

PDF: 137
- PDF
Lenalidomide (Revlimid®) in patients with cutaneous T-cell lymphoma

C Querfeld, TM Kuzel, J Guitart, ST Rosen

https://doi.org/10.4081/hmr.v3i1.546

244

PDF: 515
- PDF
NOTCH1: a therapeutic target for T cell acute lymphoblastic leukemia/lymphoma

V Tosello, A Ferrando

https://doi.org/10.4081/hmr.v3i1.547

123

PDF: 301
- PDF
Pediatric T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma therapy

A Pession, R Masetti, R Rondelli

https://doi.org/10.4081/hmr.v3i1.548

282

PDF: 270
- PDF
T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma: therapy in adults

M Bonifacio, O Perbellini, G Pizzolo

https://doi.org/10.4081/hmr.v3i1.549

210

PDF: 2337
- PDF
Prognostic factors in cutaneous T-cell lymphoma

R Willemze

https://doi.org/10.4081/hmr.v3i1.550

193

PDF: 1488
- PDF
High-dose therapy and autotransplantation in peripheral T-cell lymphoma and cutaneous T-cell lymphoma

P Reimer

https://doi.org/10.4081/hmr.v3i1.551

142

PDF: 325
- PDF
Allogeneic transplantation for peripheral and cutaneous T-cell lymphomas

P Corradini, A Dodero, G Lambertenghi-Deliliers, F Onida

https://doi.org/10.4081/hmr.v3i1.552

204

PDF: 157
- PDF